from24/7 Wall St.2 months agoHims & Hers Shows It's More Than Just GLP-1 DrugsHims & Hers reported a remarkable 111% revenue increase to $586 million, driving its stock up 18%, alongside a 345% net income rise.Growth hacking
from24/7 Wall St.2 months agoHims & Hers (HIMS) Blows Out Earnings ExpectationsHims & Hers Health reports strong Q1 2025 performance with 111% revenue increase year-over-year and robust subscriber growth.
Healthfrom24/7 Wall St.5 months agoHims & Hers (HIMS) Down 21% - Is the GLP-1 Gravy Train Over?Hims & Hers Health faces a significant stock drop due to the end of the Ozempic shortage, impacting its compounded drug market.